AACR 2023 Poster 2980

HX009, A First-in-class PD1xCD47 BsAb, Demonstrated Anti-AML Activity in PDX Models

Annie An², Jinping Liu², Hang Ke¹, Steven Xiong², Xiaolong Tu², Lei Zhang¹, Faming Zhang¹, Henry Li<sup>1

1</sup>Hanx Biopharmaceuticals, Ltd., 
²Crown Bioscience Inc., 218 Xinghu Street, Suzhou, Jiangsu, 215000, China

The poster presents preclinical data on a novel bispecific antibody, HX009, designed to target CD47 and PD-1 for the treatment of acute myeloid leukemia (AML). CD47 is a "don't eat me" receptor that prevents phagocytosis of tumor cells by macrophages. While CD47 inhibitors have been tested in AML patients, their poor efficacy and safety profile have limited their success. HX009 is a promising approach to reduce toxicity and increase efficacy through engineered dual targeting. The poster outlines the methods and results of testing HX009 on three AML patient-derived xenograft models, demonstrating its anti-AML activity and correlation to CD47 expression levels.

Download this Poster to Discover:

• How HX009, a novel bispecific antibody dual targeting PD-1 and CD47, has shown anti-AML activity in preclinical AML-PDX models.
  
  
• The correlation between the anti-AML activity of HX009 and the expression levels of CD47, a positive predictive biomarker.
  
  
• How HX009 could be a potential candidate for CD47 inhibition in AML and could be further evaluated as a potential immunotherapy.

Download the Poster Now!